$EKSO
EKSO BIONICS HOLDINGS, INC.

2017 Q3 Form 10-Q Financial Statement

#000114420417057303 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $1.597M $1.596M
YoY Change 0.06% -45.25%
Cost Of Revenue $1.053M $1.193M
YoY Change -11.74% -51.25%
Gross Profit $544.0K $403.0K
YoY Change 34.99% -13.89%
Gross Profit Margin 34.06% 25.25%
Selling, General & Admin $5.640M $5.053M
YoY Change 11.62% 28.38%
% of Gross Profit 1036.76% 1253.85%
Research & Development $1.986M $2.216M
YoY Change -10.38% 29.36%
% of Gross Profit 365.07% 549.88%
Depreciation & Amortization $420.0K $470.0K
YoY Change -10.64% 104.35%
% of Gross Profit 77.21% 116.63%
Operating Expenses $7.610M $7.269M
YoY Change 4.69% 28.68%
Operating Profit -$7.066M -$6.866M
YoY Change 2.91% 32.52%
Interest Expense $165.0K $8.000K
YoY Change 1962.5% 100.0%
% of Operating Profit
Other Income/Expense, Net $731.0K -$1.612M
YoY Change -145.35% 80500.0%
Pretax Income -$6.340M -$8.480M
YoY Change -25.24% 63.39%
Income Tax
% Of Pretax Income
Net Earnings -$6.335M -$8.478M
YoY Change -25.28% 63.51%
Net Earnings / Revenue -396.68% -531.2%
Basic Earnings Per Share -$0.18 -$0.60
Diluted Earnings Per Share -$0.18 -$0.60
COMMON SHARES
Basic Shares Outstanding 34.72M shares 19.01M shares
Diluted Shares Outstanding 34.72M shares 19.01M shares

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.44M $12.80M
YoY Change 161.25% 13.88%
Cash & Equivalents $33.44M
Short-Term Investments
Other Short-Term Assets $2.190M $620.0K
YoY Change 253.23% -76.6%
Inventory $2.380M $1.920M
Prepaid Expenses
Receivables $2.170M $2.200M
Other Receivables $0.00 $30.00K
Total Short-Term Assets $40.17M $17.57M
YoY Change 128.63% 1.87%
LONG-TERM ASSETS
Property, Plant & Equipment $2.300M $2.560M
YoY Change -10.16% 6.71%
Goodwill $189.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $120.0K $90.00K
YoY Change 33.33% 63.64%
Total Long-Term Assets $3.240M $4.050M
YoY Change -20.0% -16.97%
TOTAL ASSETS
Total Short-Term Assets $40.17M $17.57M
Total Long-Term Assets $3.240M $4.050M
Total Assets $43.41M $21.62M
YoY Change 100.79% -2.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $990.0K $1.360M
YoY Change -27.21% -36.69%
Accrued Expenses $2.750M $2.310M
YoY Change 19.05% 5.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.556M $70.00K
YoY Change 2122.86% -12.5%
Total Short-Term Liabilities $6.590M $5.510M
YoY Change 19.6% -33.26%
LONG-TERM LIABILITIES
Long-Term Debt $5.368M $0.00
YoY Change
Other Long-Term Liabilities $1.780M $7.890M
YoY Change -77.44% 70.78%
Total Long-Term Liabilities $5.368M $7.890M
YoY Change -31.96% 70.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.590M $5.510M
Total Long-Term Liabilities $5.368M $7.890M
Total Liabilities $13.74M $13.39M
YoY Change 2.61% 3.96%
SHAREHOLDERS EQUITY
Retained Earnings -$109.3M
YoY Change 25.98%
Common Stock $21.00K
YoY Change -79.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.67M $8.228M
YoY Change
Total Liabilities & Shareholders Equity $43.41M $21.62M
YoY Change 100.78% -2.28%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$6.335M -$8.478M
YoY Change -25.28% 63.51%
Depreciation, Depletion And Amortization $420.0K $470.0K
YoY Change -10.64% 104.35%
Cash From Operating Activities -$8.720M -$6.440M
YoY Change 35.4% 39.39%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$130.0K
YoY Change -23.08% -67.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K -$130.0K
YoY Change -23.08% -67.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 31.54M 14.71M
YoY Change 114.41% 147000.0%
NET CHANGE
Cash From Operating Activities -8.720M -6.440M
Cash From Investing Activities -100.0K -130.0K
Cash From Financing Activities 31.54M 14.71M
Net Change In Cash 22.72M 8.140M
YoY Change 179.12% -262.48%
FREE CASH FLOW
Cash From Operating Activities -$8.720M -$6.440M
Capital Expenditures -$100.0K -$130.0K
Free Cash Flow -$8.620M -$6.310M
YoY Change 36.61% 49.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Gross Profit
GrossProfit
403000 USD
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1053000 USD
CY2017Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
767000 USD
CY2016Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
3546000 USD
CY2017Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1556000 USD
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2017Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
58000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
54000 USD
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1495000 USD
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1587000 USD
CY2016Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
101000 USD
CY2017Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
10000 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
1596000 USD
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
1597000 USD
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1123000 USD
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1045000 USD
CY2016Q3 us-gaap Cost Of Services
CostOfServices
70000 USD
CY2017Q3 us-gaap Cost Of Services
CostOfServices
8000 USD
CY2016Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1193000 USD
CY2017Q3 us-gaap Gross Profit
GrossProfit
544000 USD
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2735000 USD
CY2017Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3226000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2216000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1986000 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2318000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2414000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
7269000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
7610000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7066000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
731000 USD
CY2016Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
3016000 USD
CY2017Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
0 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6335000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11494000 USD
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-122000 USD
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000 USD
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6457000 USD
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11511000 USD
CY2017Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-16000 USD
CY2016Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
4862000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11003000 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
38000 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
631000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
4900000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
11634000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3593000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
9078000 USD
us-gaap Cost Of Services
CostOfServices
15000 USD
us-gaap Cost Of Services
CostOfServices
452000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3608000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9530000 USD
us-gaap Gross Profit
GrossProfit
1292000 USD
us-gaap Gross Profit
GrossProfit
2104000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9563000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8151000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7491000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6586000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7430000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8271000 USD
us-gaap Operating Expenses
OperatingExpenses
24958000 USD
us-gaap Operating Expenses
OperatingExpenses
23008000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-23666000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-20904000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-262000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-20000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3522000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3010000 USD
us-gaap Net Income Loss
NetIncomeLoss
-20144000 USD
us-gaap Net Income Loss
NetIncomeLoss
-17894000 USD
us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
0 USD
us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
10345000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20144000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28239000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-356000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20500000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28245000 USD
CY2017Q3 us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2016Q3 us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Restructuring Costs
RestructuringCosts
665000 USD
us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2017Q3 ekso Change In Fair Value Contingent Liabilities
ChangeInFairValueContingentLiabilities
16000 USD
CY2016Q3 ekso Change In Fair Value Contingent Liabilities
ChangeInFairValueContingentLiabilities
0 USD
ekso Change In Fair Value Contingent Liabilities
ChangeInFairValueContingentLiabilities
191000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14537000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-577000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6653000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
297000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20555000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42459000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
69000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-6000 USD
ekso Change In Fair Value Contingent Liabilities
ChangeInFairValueContingentLiabilities
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2552000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-353000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
173000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
42000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
74000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25582000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
728000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
353000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-728000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
58000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
46000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4851000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3030000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
100000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
425000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 USD
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
0 USD
us-gaap Depreciation
Depreciation
1381000 USD
us-gaap Depreciation
Depreciation
1304000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1755000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
131000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
488000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1026000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1239000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
94000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1618000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-4498000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
86000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1335000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-750000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1279000 USD
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
75000 USD
ekso Amortization Of Deferred Rent
AmortizationOfDeferredRent
-10000 USD
ekso Amortization Of Deferred Rent
AmortizationOfDeferredRent
27000 USD
us-gaap Accretion Expense
AccretionExpense
72000 USD
us-gaap Accretion Expense
AccretionExpense
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
63000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
ekso Proceeds From Issuance Of Common Stock Preference Stock And Warrants
ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
42463000 USD
ekso Proceeds From Issuance Of Common Stock Preference Stock And Warrants
ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
14694000 USD
ekso Gain Loss On Change In Fair Value Contingent Liabilities
GainLossOnChangeInFairValueContingentLiabilities
72000 USD
ekso Gain Loss On Change In Fair Value Contingent Liabilities
GainLossOnChangeInFairValueContingentLiabilities
0 USD
us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
-356000 USD
CY2017Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1516000 USD
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1193000 USD
CY2017Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
198000 USD
CY2017Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
964000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
267000 USD
CY2017Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
102000 USD
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
102000 USD
CY2017Q3 us-gaap Deferred Revenue
DeferredRevenue
1927000 USD
CY2016Q4 us-gaap Deferred Revenue
DeferredRevenue
1630000 USD
CY2017Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
65000 USD
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
60000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
135000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
491000 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1648000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2349000 USD
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
363000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
56000 USD
CY2017Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
136000 USD
CY2016Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
203000 USD
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
241000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75000 USD
CY2017Q3 ekso Accrued Maintenance Current
AccruedMaintenanceCurrent
259000 USD
CY2016Q4 ekso Accrued Maintenance Current
AccruedMaintenanceCurrent
483000 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
355000 USD
CY2017Q3 ekso Accrued Clinical Cost Current
AccruedClinicalCostCurrent
99000 USD
CY2016Q4 ekso Accrued Clinical Cost Current
AccruedClinicalCostCurrent
35000 USD
CY2016Q4 ekso Product Maintenance Warranty Liabilities Current Noncurrent
ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
686000 USD
ekso Product Maintenance Warranty Expense
ProductMaintenanceWarrantyExpense
291000 USD
CY2017Q3 ekso Product Maintenance Warranty Liabilities Current Noncurrent
ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
395000 USD
CY2017Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
27 pure
us-gaap Restructuring Charges
RestructuringCharges
665000 USD
us-gaap Severance Costs1
SeveranceCosts1
480000 USD
CY2016Q4 ekso Accrueds Restructuring Current
AccruedsRestructuringCurrent
0 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
471000 USD
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
-186000 USD
CY2017Q3 ekso Accrueds Restructuring Current
AccruedsRestructuringCurrent
8000 USD
CY2017Q3 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
3000000 USD
CY2016Q4 ekso Success Fee Expenses
SuccessFeeExpenses
250000 USD
CY2016Q4 us-gaap Share Price
SharePrice
8.00
CY2017Q3 ekso Contingent Success Fee Liability
ContingentSuccessFeeLiability
13000 USD
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
6984000 USD
CY2017Q3 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0920 pure
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0896 pure
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 USD
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2139000 USD
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2333000 USD
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2333000 USD
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
440000 USD
CY2017Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
7245000 USD
CY2017Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
321000 USD
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
6924000 USD
CY2017Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
1556000 USD
CY2017Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5368000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
101000 USD
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
138000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
347000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
299000 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34720000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.87 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.82 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.79 pure
CY2017Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
50000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4437000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7007000 shares
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6559000 shares
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7007000 shares
CY2017Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
86000 USD
CY2016Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0 USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
71429000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
71429000 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59904000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59904000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21894000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21894000 shares
CY2017Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1814000 USD
CY2016Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1620000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4851000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3030000 USD
CY2017Q3 ekso Gain Loss On Repurchase Of Warrants
GainLossOnRepurchaseOfWarrants
-1067000 USD
CY2016Q3 ekso Gain Loss On Repurchase Of Warrants
GainLossOnRepurchaseOfWarrants
0 USD
ekso Gain Loss On Repurchase Of Warrants
GainLossOnRepurchaseOfWarrants
-1067000 USD
ekso Gain Loss On Repurchase Of Warrants
GainLossOnRepurchaseOfWarrants
0 USD
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19005000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27425000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16888000 shares
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2017Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 USD
CY2016Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 USD
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 USD
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-3030000 USD
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34720000 shares
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19005000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27425000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17595000 shares
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6335000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11494000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20144000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31269000 USD
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
707000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0126 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0183 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0229 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0124 pure
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0183 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0194 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0125 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0178 pure
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
650000 USD
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1755000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2552000 USD
CY2017Q3 us-gaap Deferred Costs
DeferredCosts
0 USD
CY2016Q4 us-gaap Deferred Costs
DeferredCosts
0 USD
CY2017Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2017Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34000000 USD
ekso Class Of Warrant Or Right Repurchased
ClassOfWarrantOrRightRepurchased
-1866000 shares
ekso Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
371000 shares
ekso Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
2066000 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3597000 shares
CY2017Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3426000 shares
CY2017Q3 us-gaap Share Price
SharePrice
1.21
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P3Y3M
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0166 pure
ekso Stock Conversion Price
StockConversionPrice
3.74
CY2017Q3 us-gaap Inventory Gross
InventoryGross
2480000 USD
CY2016Q4 us-gaap Inventory Gross
InventoryGross
1658000 USD
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7 reverse
CY2017Q3 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
86000 USD
CY2016Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
0 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1610000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
984000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
626000 USD
CY2017Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
131000 USD
CY2017Q3 ekso Shares Subscription Description
SharesSubscriptionDescription
1.1608
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Substantial Doubt About Going Concern Managements Plans Substantial Doubt Alleviated
SubstantialDoubtAboutGoingConcernManagementsPlansSubstantialDoubtAlleviated
In 2017, management has taken several actions to alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern that existed as on the date of issuance of the December 31, 2016 consolidated financial statements including but not limited to the following: streamlining its operations and reducing its workforce by approximately 27 employees to lower operating expenses and reduce cash burn. sold an aggregate of 3,732 shares of its common stock in a registered direct offering for net proceeds of $10,919. sold an aggregate of 13,465 shares of its common stock in a rights offering for net proceeds of $13,179 and 20,535 shares of its common stock to the backstop investor in a private placement in conjunction with the rights offering for proceeds of $20,535. The Company intends to use these proceeds to broaden its footprint in Asia, support research, development and commercialization activities, and for working capital.
ekso Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
417000 USD
ekso Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
167000 USD
ekso Repurchase Of Warrants And Share Issuance
RepurchaseOfWarrantsAndShareIssuance
2245000 USD
ekso Repurchase Of Warrants And Share Issuance
RepurchaseOfWarrantsAndShareIssuance
0 USD
ekso Warrant Issued
WarrantIssued
3301000 USD
ekso Warrant Issued
WarrantIssued
0 USD
ekso Supply Earnout
SupplyEarnout
189000 USD
ekso Supply Earnout
SupplyEarnout
0 USD
ekso Sales Earnout
SalesEarnout
47000 USD
ekso Sales Earnout
SalesEarnout
0 USD
ekso Cumulative Retrospective Adjustment To Retained Earnings
CumulativeRetrospectiveAdjustmentToRetainedEarnings
171000 USD
ekso Cumulative Retrospective Adjustment To Retained Earnings
CumulativeRetrospectiveAdjustmentToRetainedEarnings
0 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Concentration of Credit Risk and Other Risks and Uncertainties</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &#160;We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of September 30, 2017 and December 31, 2016.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of September 30, 2017, we had one customer with an accounts receivable balance totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our total accounts receivable (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13</font>%) compared with three customers as of December 31, 2016 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>%).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In the three months ended September 30, 2017, we had one customer with&#160;sales of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of total revenue (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16</font>%), compared with&#160;one customer&#160;in the three months ended September 30, 2016 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font>%). In the nine months ended September 30, 2017 and 2016, we had no customers with sales of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of total revenue.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001144204-17-057303-index-headers.html Edgar Link pending
0001144204-17-057303-index.html Edgar Link pending
0001144204-17-057303.txt Edgar Link pending
0001144204-17-057303-xbrl.zip Edgar Link pending
ekso-20170930.xml Edgar Link completed
ekso-20170930.xsd Edgar Link pending
ekso-20170930_cal.xml Edgar Link unprocessable
ekso-20170930_def.xml Edgar Link unprocessable
ekso-20170930_lab.xml Edgar Link unprocessable
ekso-20170930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv477869_10q.htm Edgar Link pending
tv477869_ex31-1.htm Edgar Link pending
tv477869_ex31-2.htm Edgar Link pending
tv477869_ex32-1.htm Edgar Link pending
tv477869_ex32-2.htm Edgar Link pending